Vectura Group plc Update on UK GSK patent litigation

TIDMVEC

Vectura Group plc

13 December 2018

Update on UK GSK patent litigation

Chippenham, UK - 13 December 2018: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") reports that earlier today judgement was handed down in the action brought against it by GlaxoSmithKline (GSK) in the UK Courts in relation to certain additional patents under the patent licence and option agreement with Vectura dated 5th August 2010, with the judgement overall ruling in favour of GSK.

We are disappointed by the result and are reviewing the decision in detail with our advisors. We will be considering our options, which could include seeking permission to appeal.

Whilst any potential indirect effect of this on the US proceedings pending against GSK will be considered, Vectura believes that this will not materially affect those proceedings.

- Ends-

For more information, please contact:

 
Vectura Group plc 
David Ginivan - VP Corporate Communications                         [phone] 
 Julia Wilson - Director Investor Relations                          [phone] 
 Consilium Strategic Communications                                 [phone] 
Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley 
 

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

Vectura has eight key inhaled, two non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork.

Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies.

For further information, please visit Vectura's website at www.vectura.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAUOUURWKAUAAA

(END) Dow Jones Newswires

December 13, 2018 07:34 ET (12:34 GMT)